Brigham Young University v. Pfizer, Inc.

281 F.R.D. 507, 2012 WL 830445, 2012 U.S. Dist. LEXIS 32181
CourtDistrict Court, D. Utah
DecidedMarch 9, 2012
DocketNo. 2:06-cv-890 TS
StatusPublished
Cited by8 cases

This text of 281 F.R.D. 507 (Brigham Young University v. Pfizer, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Utah primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Brigham Young University v. Pfizer, Inc., 281 F.R.D. 507, 2012 WL 830445, 2012 U.S. Dist. LEXIS 32181 (D. Utah 2012).

Opinion

MEMORANDUM DECISION AND ORDER DENYING MOTION FOR PERMISSION TO PROVIDE CERTAIN DOCUMENTS LABELED AS CONFIDENTIAL UNDER THE PROTECTIVE ORDER

BROOKE C. WELLS, United States Magistrate Judge.

Before the Court is Plaintiffs Brigham Young University and Dr. Daniel Simmons (collectively BYU) Motion For Permission to Provide Certain Documents Labeled as Confidential Under the Protective Order.1 On February 28, 2012 the matter came before the Court in an expedited manner for oral argument. BYU was represented by James Jardine, Mark Bettilyon and Dave Thomas. Defendants Pfizer, Inc. et al. (collectively Pfizer) were represented by Brent Hatch and Phillip Russell. As set forth below, the Court finds BYU has failed to demonstrate [509]*509good cause to modify the protective order. As such, the Court DENIES BYU’s motion.

BACKGROUND

Plaintiffs move this Court for permission to provide certain documents that Pfizer has labeled as confidential or highly confidential to Teva Pharmaceuticals, a third-party who is not involved in this litigation. These documents include “copies of 22 motions, including responses, accompanying exhibits, and orders resolving the same, along with the expert reports exchanged in this case”2 (Designated Documents). Because the Designated Documents are labeled as confidential or highly confidential, BYU is prohibited from sharing them with Teva under the terms of the blanket Protective Order entered into by BYU and Pfizer.

Teva is a generic drug manufacturer and a competitor with Pfizer. Teva was previously involved in COX-2 litigation with Pfizer, but did not prevail on its claims at trial or on appeal.3 Teva learned about the instant litigation involving BYU’s co-ownership claims of various COX-2 related patents and seeks to “review the Designated Documents as part of its due diligence in deciding whether to enter into an option agreement with BYU, pending the outcome of the inventorship claims in this litigation.” 4 To this end, Teva contacted BYU and expressed an interest in obtaining a license from BYU to utilize the co-inventorship rights, if they are eventually obtained in this suit. “Teva has also expressed a willingness to make a substantial upfront payment to BYU that is not dependent upon the outcome of the litigation.”5 But, before doing so, Teva would like to review the Designated Documents.

Thus, the question before the Court is whether it should amend the stipulated, blanket protective order to allow the disclosure of protected confidential documents so that a party can enter into a business transaction? This is not the more common question that has come before courts concerning whether or not confidential documents can be used in another court for separate litigation.6 Or, even the rare question concerning the establishment of a library to house “pleadings, discovery material, rulings of the court, briefs, requested instructions, the entire transcript, and all exhibits [from trial]”7 that has arisen previously. Rather, the instant matter comes down to the desire of one party to share confidential documents with a third-party, so that it can receive a “substantial upfront payment” and enter into a licensing agreement with that third-party. This precise issue has not been addressed by the Tenth Circuit. And, as represented by counsel for BYU during oral argument, there is no case allowing it, but there has been no case disallowing it either.8

DISCUSSION

Courts have the inherent power to modify protective orders, including protective orders arising from a stipulation by the parties.9 The Protective Order in this case provides a procedure for modification. Paragraph 25 of the Protective Order states:

[510]*510Nothing in this Protective Order shall prejudice the right of any party, or any third party, to seek relief form the Court, upon good cause shown, from any of the restrictions provided above or to impose additional restriction on the disclosure of any information or material.10

Courts have applied a number of factors in deciding whether to modify a protective order. Such factors include: “the reason and purpose for a modification, whether a party has alternative means available to acquire the information, the type of protective order which is at issue, and the type of materials or documents which are sought.”11

The party seeking to modify a protective order bears the burden of showing good cause for the modification.12 Some courts require a showing of a compelling need or extraordinary circumstance.13 The Tenth Circuit, however, requires the showing of a reasonable need.14 Courts have found the reasonable need showing met when a party needs discovery from another litigation to avoid the efforts of duplicative discovery.15 The efficiency considerations of “saving time and effort in the collateral case by avoiding duplicative discovery”16 are to be balanced against the countervailing current that is created by modifying a protective order. Allowing modification of protective orders for the benefit of third-parties undermines the effectiveness of that order — and conceivably other orders using similar language — in creating a more efficient discovery process.17

As set forth by the Tenth Circuit, a court should refrain from issuing discovery orders applicable to collateral litigation.18 Otherwise, a court may be involved in litigating issues not before it creating unnecessary additional burdens on both the court and the parties.19

Modifying protective orders can also have the negative effect of creating distrust for such orders. Stipulated protective orders have become standard practice in complex cases and are valuable in creating a reliable dependable discovery process.20 Such orders allow the parties to make full disclosure in discovery without fear of unauthorized access to sensitive information and they reduce the expense and delay of endless discovery disputes.21 “Reliance on protective orders and the diligence of counsel in observing them is fundamental to litigation between competitors.”22 In short, they help promote the overriding goal of the Federal Rules of Civil Procedure to “secure the just, speedy, and inexpensive determination of every action and proceeding.”23

In addition the type of protective order sought to be modified has an impact on the decision to modify. Great care must be exercised before modifying a protective order entered pursuant to Rule 26(c).24 In contrast, a blanket protective order, like the one [511]*511in the instant dispute, is a Rule 29 stipulation between the parties and is not treated with as much deference.25

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
281 F.R.D. 507, 2012 WL 830445, 2012 U.S. Dist. LEXIS 32181, Counsel Stack Legal Research, https://law.counselstack.com/opinion/brigham-young-university-v-pfizer-inc-utd-2012.